1.63
-0.02 (-1.21%)
| Penutupan Terdahulu | 1.65 |
| Buka | 1.62 |
| Jumlah Dagangan | 583,676 |
| Purata Dagangan (3B) | 1,446,375 |
| Modal Pasaran | 116,076,136 |
| Harga / Jualan (P/S) | 17.74 |
| Harga / Buku (P/B) | 2.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2026 |
| Margin Operasi (TTM) | -9,653.85% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.34% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | -49.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.61 M |
| Pulangan Atas Aset (ROA TTM) | -31.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ovid Therapeutics Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.25 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 55.97% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ally Bridge Group (Ny) Llc | 31 Dec 2025 | 1,785,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.00 (LifeSci Capital, 145.40%) | Beli |
| Median | 3.00 (84.05%) | |
| Rendah | 2.00 (HC Wainwright & Co., 22.70%) | Beli |
| Purata | 3.00 (84.05%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 1.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Dec 2025 | 2.00 (22.70%) | Beli | 1.79 |
| LifeSci Capital | 22 Dec 2025 | 4.00 (145.40%) | Beli | 1.79 |
| Roth Capital | 11 Dec 2025 | 3.00 (84.05%) | Beli | 1.65 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2025 | Pengumuman | Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |